{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-089773","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.774125+00:00","generated_at":"2026-05-17T06:38:54.886645+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioXcel completes enrollment for mCGI-S/PEC study; sNDA submission expected Q1 2026","bullets":["Open-label study of ~30 patients evaluating mCGI-S vs PEC scale enrolled on Sept 13, 2025; results due Q4 2025.","sNDA for BXCL501 SERENITY At-Home program planned for Q1 2026, incorporating this and prior Phase 3 safety data.","Raised $37.3M from July 1 to Sept 15, 2025 via ATM ($27.6M) and warrant exercises ($9.7M).","As of Sept 12, 2025, shares outstanding totaled 19,646,801; cash expected to fund operations into Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-089773","json":"https://secwatch.observer/filing/0001104659-25-089773.json","markdown":"https://secwatch.observer/filing/0001104659-25-089773.md","text":"https://secwatch.observer/filing/0001104659-25-089773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925089773/0001104659-25-089773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925089773/tm2526080d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:38:54.886645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}